Comparison of the efficacy and safety of drug therapies for macular edema secondary to central retinal vein occlusion

Qian, Tianwei; Zhao, Mengya; Wan, Yongjing; Li, Meng-xiao; Xu, Xun

doi:10.1136/bmjopen-2018-022700

Cited by 21 publications

(26 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings were contrasting to the findings of Son BK et al in which significant reduction in CMT was observed in both the groups at 6 month follow up but the observed difference was statistically not significant between the groups [9]. Qian T et al reported ranibizumab to be more effective in reducing CRT at 6 months than dexamethasone, and bevacizumab was more effective than than triamcinolone but less effective than Ranibizumab [13].…”

Section: Original Research Articlecontrasting

confidence: 69%

“…These findings were in contrast to the findings of Son BK et al in which significant improvement in visual acuity was observed in both the groups at 6 month follow up as compared to baseline but the difference in improvement of visual acuity between the groups was statistically not significant [9]. Qian T et al in their study compared the efficacy and safety of drug therapies (aflibercept, ranibizumab, bevacizumab, pegaptanib, dexamethasone, triamcinolone) for macular edema secondary to central retinal vein occlusion and observed that only aflibercept and ranibizumab had a significantly better efficacy than the sham/placebo group [13]. The BRAVO trial assessed the efficacy of ranibizumab in patients with BRVO and found a significant improvement in visual acuity and a reduction in central foveal thickness in the ranibizumab-treated group compared to a sham group [13].…”

Section: Discussionmentioning

confidence: 99%

“…Qian T et al in their study compared the efficacy and safety of drug therapies (aflibercept, ranibizumab, bevacizumab, pegaptanib, dexamethasone, triamcinolone) for macular edema secondary to central retinal vein occlusion and observed that only aflibercept and ranibizumab had a significantly better efficacy than the sham/placebo group [13]. The BRAVO trial assessed the efficacy of ranibizumab in patients with BRVO and found a significant improvement in visual acuity and a reduction in central foveal thickness in the ranibizumab-treated group compared to a sham group [13].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Comparison of ranibizumab and bevacizumab for macular edema associated with retinal vein occlusion

Sharma

Jat

Singh

et al. 2019

Trop J Ophthalmol Otolaryngol

View full text Add to dashboard Cite

To assess the effectiveness of intravitreal ranibizumab compared with bevacizumab for the treatment of macular edema associated with retinal vein occlusion (RVO). Methods: This was a retrospective study of 64 eyes with macular edema associated with RVO. Patients received either 1.25 mg of intravitreal bevacizumab (n = 32) or 0.5 mg of intravitreal ranibizumab (n = 32). Visual acuity, clinical bio-microscopic examination and central macular thickness (CMT) by Optical Coherence Tomography (OCT) was assessed at 6 weeks post injection. The CMT before and six weeks after the injection as assessed by OCT were compared. Statistical analysis was performed using paired student t-test. The improvement in CMT was also compared between the two groups, statistical analysis was performed using un-paired student t-test. Results: The best-corrected visual acuity significantly improved from logarithm of the minimal angle of resolution (logMAR) 0.792 ±0.36 at baseline to 0.575 ± 0.34 at 6 weeks in the bevacizumab group (p =0.001) and from logMAR 0.851 ± 0.35 at baseline to 0.336 ± 0.20 at 6 weeks in the ranibizumab group (p = 0.001), which is statistically significant difference. The reduction in CMT was from 545.44 ± 176.43 μm at baseline to 378.34 ±95.13 at 6 weeks in the bevacizumab group (p = 0.001) and 524.25± 195.94 μm at baseline to 243±80.72 μm at 6 weeks in the ranibizumab group (p=0.001) which was also a statistically significant difference (p = 0.001). Conclusions: Both ranibizumab and bevacizumab were effective for the treatment of RVO. The visual outcome and reduction in macular thickness was better by ranibizumab at the earliest follow-up of 6 weeks.

show abstract

Section: Original Research Articlecontrasting

confidence: 69%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of ranibizumab and bevacizumab for macular edema associated with retinal vein occlusion

Sharma

Jat

Singh

et al. 2019

Trop J Ophthalmol Otolaryngol

View full text Add to dashboard Cite

show abstract

“…; Qian et al. ). However, a concurrent efficacy study encompassing these diseases distinguishes the treatment responses among them is not available.…”

Section: Discussionmentioning

confidence: 98%

Implication of inflammatory cytokines in the aqueous humour for management of macular diseases

Qian¹,

Wang²,

Chen³

et al. 2019

Acta Ophthalmologica

View full text Add to dashboard Cite

Purpose: To characterize profile of cytokines in aqueous humour of common macular diseases during intravitreal anti-VEGF therapy. Methods: Aqueous humour from eyes with central retinal vein occlusion (CRVO), branch retinal vein occlusion (BRVO), diabetic macular oedema (DME), neovascular age-related macular degeneration (nAMD) or pathologic myopia associated choroidal neovascularization (pmCNV) was sampled prior to 1st (n = 144) and 2nd (n = 48) intravitreal anti-VEGF therapy. Cytokines including vascular endothelium growth factor (VEGF), intercellular adhesion molecule 1 (ICAM-1) and interleukin 6 (IL-6) were quantitated and analysed along with retinal thickness data by optical coherence tomography (OCT) across two intravitreal injections and five macular disease types. Results: ICAM-1, IL-6 and VEGF are positively associated in the aqueous humour of naive eyes (r = 0.39-0.77, p = 0.018 to <0.0001). ICAM-1, VEGF and IL-6 were significantly higher in CRVO and DME while lowest in pmCNV (p < 0.0001). Reduction of central retinal thickness (CRT) as a favourable response to anti-VEGF therapy was in the order of CRVO, BRVO, DME and nAMD/pmCNV (p < 0.0001). The strongest predictor for favourable CRT reduction was baseline CRT (p < 0.0001) followed by baseline ICAM-1 (p = 0.04). After the 1st intravitreal anti-VEGF therapy, VEGF in aqueous humour lowered significantly but ICAM-1 and IL-6 levels remained unchanged. ICAM-1 was not predictive for CRT reduction following 2nd anti-VEGF therapy. Conclusion: Rate of cytokine production is disease-dependent and higher in CRVO and DME. Anatomical response to intravitreal anti-VEGF therapy is disease-specific and best in RVO patients. A combination therapy using both anti-VEGF and anti-inflammatory therapeutics may be superior to single anti-VEGF therapy, at least for RVO and DME.

show abstract

“…[ 2 ] Intraocular pressure (IOP) elevation has proven to be one of their major side effects. [ 3 , 4 ] Nevertheless, corticosteroids in different dosage forms are indispensable in treating inflammatory eye diseases. In addition, corticosteroids are the mainstay of treatment in postoperative ocular management.…”

Section: Introductionmentioning

confidence: 99%

Corticosteroid-induced intraocular pressure elevation in the pediatric patients

Zheng

Cai

et al. 2021

Medicine

View full text Add to dashboard Cite

Background: Corticosteroids have been one of the most frequently used therapeutics in ophthalmology over the past decades, known for their potent anti-inflammatory and immunosuppressive actions. Intraocular pressure elevation has proven to be a significant ocular side effect that could accompany steroid use. However, the information on ocular-hypertensive corticosteroid response is scant in children. We aim to systematically describe the corticosteroid-induced intraocular pressure elevation in the pediatric age group. Methods: PubMed, Embase, Web of Science, Cochrane Library, Latin American and Caribbean Health Sciences Literature, and the Chinese Biomedical Literature database will be searched for potential articles from database inception to April 29, 2021. No language restrictions will be applied. Studies involving patients less than 18 years old receiving corticosteroids will be included. We will screen abstracts for relevance, extract data, and assess the risk of bias in duplicate. We will rate the certainty of evidence using the Grading of Recommendations Assessment Development and Evaluation approach. The primary outcome will be the intraocular pressure in pediatric patients group. We will provide a narrative synthesis of the findings. Results: The systematic review will provide high-quality evidence to assess the relationship between dosage, frequency, route of administration, and duration of corticosteroid on intraocular pressure in children. Conclusion: The systematic review will provide evidence to assess the safety of corticosteroid for ocular diseases in pediatric population. PROSPERO registration number: CRD42021252298.

show abstract

Comparison of the efficacy and safety of drug therapies for macular edema secondary to central retinal vein occlusion

Cited by 21 publications

References 85 publications

Comparison of ranibizumab and bevacizumab for macular edema associated with retinal vein occlusion

Comparison of ranibizumab and bevacizumab for macular edema associated with retinal vein occlusion

Implication of inflammatory cytokines in the aqueous humour for management of macular diseases

Corticosteroid-induced intraocular pressure elevation in the pediatric patients

Contact Info

Product

Resources

About